ENHERTU® approved in Canada as the first and only HER2-directed therapy for patients with HR-positive HER2-low or HER2-ultralow metastatic breast cancer, following disease progression after one or more endocrine therapies
Based on the DESTINY-Breast06 phase III trial results demonstrating statistically significant and clinically meaningful progression-free survival benefit in patients treated with Enhertu vs. conventional chemotherapy Health Canada has granted a Notice of Compliance (NOC) for Enhertu® (trastuzumab deruxtecan)for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC […]